CN115023428A - 嘧啶并吡咯类化合物 - Google Patents
嘧啶并吡咯类化合物 Download PDFInfo
- Publication number
- CN115023428A CN115023428A CN202180010090.0A CN202180010090A CN115023428A CN 115023428 A CN115023428 A CN 115023428A CN 202180010090 A CN202180010090 A CN 202180010090A CN 115023428 A CN115023428 A CN 115023428A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- formula
- acceptable salt
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical class C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 169
- 150000003839 salts Chemical class 0.000 claims abstract description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 229910052731 fluorine Inorganic materials 0.000 claims description 60
- 229910052801 chlorine Inorganic materials 0.000 claims description 57
- 229910052740 iodine Inorganic materials 0.000 claims description 56
- 229910052794 bromium Inorganic materials 0.000 claims description 55
- 125000000217 alkyl group Chemical group 0.000 claims description 47
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims description 44
- 125000000623 heterocyclic group Chemical group 0.000 claims description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims description 40
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 37
- 238000006467 substitution reaction Methods 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 26
- 125000003118 aryl group Chemical group 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 17
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 13
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 12
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 11
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 11
- 125000004104 aryloxy group Chemical group 0.000 claims description 11
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 11
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims description 11
- 108010024121 Janus Kinases Proteins 0.000 claims description 10
- 102000015617 Janus Kinases Human genes 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 24
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 abstract description 22
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 abstract description 21
- 229940124291 BTK inhibitor Drugs 0.000 abstract description 4
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 108
- 238000006243 chemical reaction Methods 0.000 description 107
- -1 pyrimidopyrrole compound Chemical class 0.000 description 105
- 230000015572 biosynthetic process Effects 0.000 description 96
- 238000003786 synthesis reaction Methods 0.000 description 96
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 90
- 239000000243 solution Substances 0.000 description 83
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 71
- 201000006417 multiple sclerosis Diseases 0.000 description 71
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 54
- 239000000460 chlorine Substances 0.000 description 49
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
- 230000002829 reductive effect Effects 0.000 description 47
- 239000000203 mixture Substances 0.000 description 41
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 40
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 35
- 239000012071 phase Substances 0.000 description 33
- 238000005481 NMR spectroscopy Methods 0.000 description 29
- 239000000047 product Substances 0.000 description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
- 239000012074 organic phase Substances 0.000 description 27
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 23
- 239000012043 crude product Substances 0.000 description 22
- 239000000706 filtrate Substances 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 238000000746 purification Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 19
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- 239000007788 liquid Substances 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 229920006395 saturated elastomer Polymers 0.000 description 16
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 238000004237 preparative chromatography Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 102000042838 JAK family Human genes 0.000 description 14
- 108091082332 JAK family Proteins 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 125000002619 bicyclic group Chemical group 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 230000026731 phosphorylation Effects 0.000 description 13
- 238000006366 phosphorylation reaction Methods 0.000 description 13
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 238000002953 preparative HPLC Methods 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 239000003208 petroleum Substances 0.000 description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 150000002430 hydrocarbons Chemical group 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 8
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
- 125000002950 monocyclic group Chemical group 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 229910000160 potassium phosphate Inorganic materials 0.000 description 8
- 235000011009 potassium phosphates Nutrition 0.000 description 8
- 125000006413 ring segment Chemical group 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 7
- WTQSCKVVSCTTJU-UHFFFAOYSA-N ClC=1N=C(C2=C(N=1)N(C=C2C1CC1)COCC[Si](C)(C)C)Cl Chemical compound ClC=1N=C(C2=C(N=1)N(C=C2C1CC1)COCC[Si](C)(C)C)Cl WTQSCKVVSCTTJU-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical class [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 7
- MEOZFUYXLCDYGA-UHFFFAOYSA-N azepane-1-carboxylic acid Chemical compound OC(=O)N1CCCCCC1 MEOZFUYXLCDYGA-UHFFFAOYSA-N 0.000 description 7
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- XSXZKGLWPRJOMM-UHFFFAOYSA-N 1-(1-methylpiperidin-4-yl)pyrazol-4-amine Chemical compound C1CN(C)CCC1N1N=CC(N)=C1 XSXZKGLWPRJOMM-UHFFFAOYSA-N 0.000 description 6
- GOSIUUKDKZGBNS-UHFFFAOYSA-N 2-[(2,4-dichloro-5-iodopyrrolo[2,3-d]pyrimidin-7-yl)methoxy]ethyl-trimethylsilane Chemical compound N1=C(Cl)N=C2N(COCC[Si](C)(C)C)C=C(I)C2=C1Cl GOSIUUKDKZGBNS-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 125000003566 oxetanyl group Chemical group 0.000 description 6
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 6
- NJCRQFJRXAZYEJ-GQCTYLIASA-N (e)-2-cyano-4,4-dimethylpent-2-enoic acid Chemical compound CC(C)(C)\C=C(/C#N)C(O)=O NJCRQFJRXAZYEJ-GQCTYLIASA-N 0.000 description 5
- RIRSSBIXHXMTLS-UHFFFAOYSA-N 2,4-dichloro-5-iodo-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC(Cl)=C2C(I)=CNC2=N1 RIRSSBIXHXMTLS-UHFFFAOYSA-N 0.000 description 5
- CGWVSQGYLZDALB-LJQANCHMSA-N CCN1N=CC(NC2=NC(=C3C(N(CO)C=C3C3=CC=CC=C3)=N2)N[C@H]2CN(C(=O)C=C)CCC2)=C1 Chemical compound CCN1N=CC(NC2=NC(=C3C(N(CO)C=C3C3=CC=CC=C3)=N2)N[C@H]2CN(C(=O)C=C)CCC2)=C1 CGWVSQGYLZDALB-LJQANCHMSA-N 0.000 description 5
- CHHZKSPMRQUNOI-UHFFFAOYSA-N C[Si](C)(C)CCOCN(C=C1C2=CC=CC=C2)C2=C1C(Cl)=NC(Cl)=N2 Chemical compound C[Si](C)(C)CCOCN(C=C1C2=CC=CC=C2)C2=C1C(Cl)=NC(Cl)=N2 CHHZKSPMRQUNOI-UHFFFAOYSA-N 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 5
- MBGJHFWMUDQTNY-MOPGFXCFSA-N F[C@H]1[C@H](CN(CC1)C(C=C)=O)OC=1C2=C(N=C(N=1)NC=1C=NN(C=1)C1CCN(CC1)C)NC=C2 Chemical compound F[C@H]1[C@H](CN(CC1)C(C=C)=O)OC=1C2=C(N=C(N=1)NC=1C=NN(C=1)C1CCN(CC1)C)NC=C2 MBGJHFWMUDQTNY-MOPGFXCFSA-N 0.000 description 5
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 239000012295 chemical reaction liquid Substances 0.000 description 5
- 229910052805 deuterium Inorganic materials 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 239000012047 saturated solution Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
- GZZNBQLBGSVOOZ-UHFFFAOYSA-N 1-(oxan-4-yl)pyrazol-4-amine Chemical compound C1=C(N)C=NN1C1CCOCC1 GZZNBQLBGSVOOZ-UHFFFAOYSA-N 0.000 description 4
- DSEUPOQICWKBQE-UHFFFAOYSA-N 1-methyl-4-(4-nitropyrazol-1-yl)piperidine Chemical compound C1CN(C)CCC1N1N=CC([N+]([O-])=O)=C1 DSEUPOQICWKBQE-UHFFFAOYSA-N 0.000 description 4
- RTXZVXGBCVRHBZ-QGZVFWFLSA-N C1C(N2N=CC(NC3=NC(=C4C(=N3)NC=C4C3CC3)N[C@H]3CN(C(=O)C=C)CCC3)=C2)CCOC1 Chemical compound C1C(N2N=CC(NC3=NC(=C4C(=N3)NC=C4C3CC3)N[C@H]3CN(C(=O)C=C)CCC3)=C2)CCOC1 RTXZVXGBCVRHBZ-QGZVFWFLSA-N 0.000 description 4
- JSZOAAWCNFCSFQ-GOSISDBHSA-N C1C(N2N=CC(NC3=NC(=C4C(N(CO)C=C4C4CC4)=N3)N[C@H]3CN(C(=O)C=C)CCC3)=C2)CCOC1 Chemical compound C1C(N2N=CC(NC3=NC(=C4C(N(CO)C=C4C4CC4)=N3)N[C@H]3CN(C(=O)C=C)CCC3)=C2)CCOC1 JSZOAAWCNFCSFQ-GOSISDBHSA-N 0.000 description 4
- ZGRFIZYRECCQPH-MRXNPFEDSA-N C1C(N2N=CC(NC3=NC(=C4C(N(CO)C=C4C4CC4)=N3)N[C@H]3CNCCC3)=C2)CCOC1 Chemical compound C1C(N2N=CC(NC3=NC(=C4C(N(CO)C=C4C4CC4)=N3)N[C@H]3CNCCC3)=C2)CCOC1 ZGRFIZYRECCQPH-MRXNPFEDSA-N 0.000 description 4
- IGQAUMFCOZZPSE-OIISXLGYSA-N C1[C@@H](N2N=CC(NC3=NC(=C4C(=N3)NC=C4)O[C@@H]3[C@@H](CCN(C(=O)C=C)C3)F)=C2)COC1 Chemical compound C1[C@@H](N2N=CC(NC3=NC(=C4C(=N3)NC=C4)O[C@@H]3[C@@H](CCN(C(=O)C=C)C3)F)=C2)COC1 IGQAUMFCOZZPSE-OIISXLGYSA-N 0.000 description 4
- WQMPRNGOFUNLIA-QGZVFWFLSA-N CCN1N=CC(NC2=NC(=C3C(N(CO)C=C3C3=CC=CC=C3)=N2)N[C@@H]2CCCNC2)=C1 Chemical compound CCN1N=CC(NC2=NC(=C3C(N(CO)C=C3C3=CC=CC=C3)=N2)N[C@@H]2CCCNC2)=C1 WQMPRNGOFUNLIA-QGZVFWFLSA-N 0.000 description 4
- QBCWNMNLNXAMRK-OAHLLOKOSA-N CCN1N=CC(NC2=NC(NC=C3C4CC4)=C3C(N[C@H](CCC3)CN3C(C=C)=O)=N2)=C1 Chemical compound CCN1N=CC(NC2=NC(NC=C3C4CC4)=C3C(N[C@H](CCC3)CN3C(C=C)=O)=N2)=C1 QBCWNMNLNXAMRK-OAHLLOKOSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- RFHWLYCWPJCJSE-GOSISDBHSA-N N1(CC)N=CC(NC2=NC(=C3C(=N2)NC=C3C2=CC=CC=C2)N[C@H]2CN(C(=O)C=C)CCC2)=C1 Chemical compound N1(CC)N=CC(NC2=NC(=C3C(=N2)NC=C3C2=CC=CC=C2)N[C@H]2CN(C(=O)C=C)CCC2)=C1 RFHWLYCWPJCJSE-GOSISDBHSA-N 0.000 description 4
- GAWQXWJEFDQVCY-CYBMUJFWSA-N N=1N(C=C(C=1)NC1=NC(=C2C(=N1)NC=C2C1CC1)N[C@H]1CN(CC1)C(=O)C=C)C Chemical compound N=1N(C=C(C=1)NC1=NC(=C2C(=N1)NC=C2C1CC1)N[C@H]1CN(CC1)C(=O)C=C)C GAWQXWJEFDQVCY-CYBMUJFWSA-N 0.000 description 4
- HLNXMJNSFRSMPX-SCSGRABISA-N N=1N(C=C(NC2=NC(=C3C(=N2)NC=C3C2CC2)N[C@@H]2CC[C@@H](N(C(=O)/C(=C/C(C)(C)C)/C#N)C2)C)C=1)C Chemical compound N=1N(C=C(NC2=NC(=C3C(=N2)NC=C3C2CC2)N[C@@H]2CC[C@@H](N(C(=O)/C(=C/C(C)(C)C)/C#N)C2)C)C=1)C HLNXMJNSFRSMPX-SCSGRABISA-N 0.000 description 4
- XLJMWDDHZYSCLY-GXTWGEPZSA-N N=1N(C=C(NC2=NC(=C3C(=N2)NC=C3C2CC2)N[C@@H]2CC[C@@H](N(C(=O)C=C)C2)C)C=1)C(F)(F)F Chemical compound N=1N(C=C(NC2=NC(=C3C(=N2)NC=C3C2CC2)N[C@@H]2CC[C@@H](N(C(=O)C=C)C2)C)C=1)C(F)(F)F XLJMWDDHZYSCLY-GXTWGEPZSA-N 0.000 description 4
- UZQNMDKDOOERAS-WDEREUQCSA-N N=1N(C=C(NC2=NC(=C3C(=N2)NC=C3F)N[C@H]2CN(C(=O)C=C)[C@H](C2)C)C=1)C Chemical compound N=1N(C=C(NC2=NC(=C3C(=N2)NC=C3F)N[C@H]2CN(C(=O)C=C)[C@H](C2)C)C=1)C UZQNMDKDOOERAS-WDEREUQCSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- SPSIFKAQQYIWHB-NXHRZFHOSA-N [C@H]1(N2N=CC(NC3=NC(O[C@@H]4[C@@H](CCN(C(=O)C=C)C4)F)=C4C=CNC4=N3)=C2)CN(CC1)C Chemical compound [C@H]1(N2N=CC(NC3=NC(O[C@@H]4[C@@H](CCN(C(=O)C=C)C4)F)=C4C=CNC4=N3)=C2)CN(CC1)C SPSIFKAQQYIWHB-NXHRZFHOSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- SBOPEFHTOFMNSD-IAWMPOBQSA-N n-[3-[2-[2-[3-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]propoxy]ethoxy]ethoxy]propyl]-n'-[3-[3-[[5-methyl-4-[3-(prop-2-enoylamino)anilino]pyrimidin-2-yl]amino]phenoxy]propyl]pentanediamide Chemical compound CC1=CN=C(NC=2C=C(OCCCNC(=O)CCCC(=O)NCCCOCCOCCOCCCNC(=O)CCCC[C@H]3[C@H]4NC(=O)N[C@H]4CS3)C=CC=2)N=C1NC1=CC=CC(NC(=O)C=C)=C1 SBOPEFHTOFMNSD-IAWMPOBQSA-N 0.000 description 4
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 3
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 3
- BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 3
- LBGSWBJURUFGLR-UHFFFAOYSA-N 1-methylpyrazol-4-amine Chemical compound CN1C=C(N)C=N1 LBGSWBJURUFGLR-UHFFFAOYSA-N 0.000 description 3
- 238000012815 AlphaLISA Methods 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- RSDXYHYKXYICOP-CVEARBPZSA-N C=CC(N(CC[C@H]1F)C[C@@H]1OC1=C(C=CN2)C2=NC(NC2=CN(C3COC3)N=C2)=N1)=O Chemical compound C=CC(N(CC[C@H]1F)C[C@@H]1OC1=C(C=CN2)C2=NC(NC2=CN(C3COC3)N=C2)=N1)=O RSDXYHYKXYICOP-CVEARBPZSA-N 0.000 description 3
- UDXDEPQZUAFKKH-RTWAWAEBSA-N CN(CC1)CCC1N1N=CC(NC2=NC(NC=C3C4CC4)=C3C(N[C@@H](CN(CC3)C(C=C)=O)[C@@H]3F)=N2)=C1 Chemical compound CN(CC1)CCC1N1N=CC(NC2=NC(NC=C3C4CC4)=C3C(N[C@@H](CN(CC3)C(C=C)=O)[C@@H]3F)=N2)=C1 UDXDEPQZUAFKKH-RTWAWAEBSA-N 0.000 description 3
- MMOJNSAWQINOMZ-SJORKVTESA-N CN(CC1)CCC1N1N=CC(NC2=NC(O[C@@H](CNCC3)[C@@H]3F)=C(C=CN3)C3=N2)=C1 Chemical compound CN(CC1)CCC1N1N=CC(NC2=NC(O[C@@H](CNCC3)[C@@H]3F)=C(C=CN3)C3=N2)=C1 MMOJNSAWQINOMZ-SJORKVTESA-N 0.000 description 3
- RBBKSKAGLMNDCU-DZGCQCFKSA-N C[C@@H](CC[C@H](C1)NC2=NC(NC3=CN(C)N=C3)=NC3=C2C(C2CC2)=CN3)N1C(C=C)=O Chemical compound C[C@@H](CC[C@H](C1)NC2=NC(NC3=CN(C)N=C3)=NC3=C2C(C2CC2)=CN3)N1C(C=C)=O RBBKSKAGLMNDCU-DZGCQCFKSA-N 0.000 description 3
- MPKSAZRZEQWXTL-LSDHHAIUSA-N C[C@@H](C[C@H](C1)NC2=NC(Cl)=NC3=C2C(F)=CN3COCC[Si](C)(C)C)N1C(OC(C)(C)C)=O Chemical compound C[C@@H](C[C@H](C1)NC2=NC(Cl)=NC3=C2C(F)=CN3COCC[Si](C)(C)C)N1C(OC(C)(C)C)=O MPKSAZRZEQWXTL-LSDHHAIUSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- IFEBYVFNQVXFOW-SFYZADRCSA-N F[C@H](CCNC1)[C@H]1OC1=NC(Cl)=NC2=C1C=CN2 Chemical compound F[C@H](CCNC1)[C@H]1OC1=NC(Cl)=NC2=C1C=CN2 IFEBYVFNQVXFOW-SFYZADRCSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- AKQXKEBCONUWCL-MRVPVSSYSA-N tert-butyl (3r)-3-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H](N)C1 AKQXKEBCONUWCL-MRVPVSSYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- HENLKZLWIDJRSC-UHFFFAOYSA-N 1-ethylpyrazol-4-amine Chemical compound CCN1C=C(N)C=N1 HENLKZLWIDJRSC-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- XDPCNPCKDGQBAN-UHFFFAOYSA-N 3-hydroxytetrahydrofuran Chemical compound OC1CCOC1 XDPCNPCKDGQBAN-UHFFFAOYSA-N 0.000 description 2
- WNGOPKGWJNIWCU-UHFFFAOYSA-N 4-nitro-1-(oxan-4-yl)pyrazole Chemical compound C1=C([N+](=O)[O-])C=NN1C1CCOCC1 WNGOPKGWJNIWCU-UHFFFAOYSA-N 0.000 description 2
- XORHNJQEWQGXCN-UHFFFAOYSA-N 4-nitro-1h-pyrazole Chemical compound [O-][N+](=O)C=1C=NNC=1 XORHNJQEWQGXCN-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 2
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 2
- IGVLQWSLOHUDTR-YUELXQCFSA-N C1[C@@H](N2N=CC(NC3=NC(=C4C(=N3)NC=C4)O[C@@H]3[C@@H](CCNC3)F)=C2)COC1 Chemical compound C1[C@@H](N2N=CC(NC3=NC(=C4C(=N3)NC=C4)O[C@@H]3[C@@H](CCNC3)F)=C2)COC1 IGVLQWSLOHUDTR-YUELXQCFSA-N 0.000 description 2
- 238000011814 C57BL/6N mouse Methods 0.000 description 2
- YWCYNKHGQRVRKS-MRXNPFEDSA-N CCN1N=CC(NC2=NC(N(CO)C=C3C4CC4)=C3C(N[C@H](CCC3)CN3C(C=C)=O)=N2)=C1 Chemical compound CCN1N=CC(NC2=NC(N(CO)C=C3C4CC4)=C3C(N[C@H](CCC3)CN3C(C=C)=O)=N2)=C1 YWCYNKHGQRVRKS-MRXNPFEDSA-N 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- ZQSBEJOSXMVPOO-UHFFFAOYSA-N CN1N=CC(NC2=NC(N(CO)C=C3Cl)=C3C(OC3CCNCCC3)=N2)=C1 Chemical compound CN1N=CC(NC2=NC(N(CO)C=C3Cl)=C3C(OC3CCNCCC3)=N2)=C1 ZQSBEJOSXMVPOO-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
- 239000004012 Tofacitinib Substances 0.000 description 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 229960001507 ibrutinib Drugs 0.000 description 2
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 2
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- CVHJEFDRBTZVEL-SFYZADRCSA-N tert-butyl (3s,4r)-3-amino-4-fluoropiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](F)[C@@H](N)C1 CVHJEFDRBTZVEL-SFYZADRCSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960001350 tofacitinib Drugs 0.000 description 2
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- RKORKXLEGJOTTK-UHFFFAOYSA-N 1-(oxetan-3-yl)pyrazol-4-amine Chemical compound C1=C(N)C=NN1C1COC1 RKORKXLEGJOTTK-UHFFFAOYSA-N 0.000 description 1
- NWEBOUMNZRJLMU-UHFFFAOYSA-N 1-(trifluoromethyl)pyrazol-4-amine Chemical compound FC(F)(F)N1N=CC(=C1)N NWEBOUMNZRJLMU-UHFFFAOYSA-N 0.000 description 1
- QQDVZDGMTMHVPZ-MRVPVSSYSA-N 1-[(3R)-1-methylpyrrolidin-3-yl]pyrazol-4-amine Chemical compound CN1CC[C@H](C1)n1cc(N)cn1 QQDVZDGMTMHVPZ-MRVPVSSYSA-N 0.000 description 1
- CGWDUHSWKSAOCN-SSDOTTSWSA-N 1-[(3r)-oxolan-3-yl]pyrazol-4-amine Chemical compound C1=C(N)C=NN1[C@H]1COCC1 CGWDUHSWKSAOCN-SSDOTTSWSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- KWVPRPSXBZNOHS-UHFFFAOYSA-N 2,4,6-Trimethylaniline Chemical compound CC1=CC(C)=C(N)C(C)=C1 KWVPRPSXBZNOHS-UHFFFAOYSA-N 0.000 description 1
- GHXBPCSSQOKKGB-UHFFFAOYSA-N 2,4-dichloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC(Cl)=C2C=CNC2=N1 GHXBPCSSQOKKGB-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- ZPCCDJKBCGVQLK-UHFFFAOYSA-N 2-[(2,4-dichloro-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl)methoxy]ethyl-trimethylsilane Chemical compound N1=C(Cl)N=C2N(COCC[Si](C)(C)C)C=C(F)C2=C1Cl ZPCCDJKBCGVQLK-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DLKPQPNIFZLRRM-PYUWXLGESA-N C1C(N2N=CC(NC3=NC(=C4C(=N3)NC=C4C3CC3)N[C@H]3CN(C(=O)C=C)CCC3)=C2)COC1 Chemical compound C1C(N2N=CC(NC3=NC(=C4C(=N3)NC=C4C3CC3)N[C@H]3CN(C(=O)C=C)CCC3)=C2)COC1 DLKPQPNIFZLRRM-PYUWXLGESA-N 0.000 description 1
- XMTNECGMWFDLOB-GOSISDBHSA-N C1C(N2N=CC(NC3=NC(=C4C(C5CC5)=CNC4=N3)N[C@@H]3CCCN(C(=O)C=C)C3)=C2)CCN(C1)C Chemical compound C1C(N2N=CC(NC3=NC(=C4C(C5CC5)=CNC4=N3)N[C@@H]3CCCN(C(=O)C=C)C3)=C2)CCN(C1)C XMTNECGMWFDLOB-GOSISDBHSA-N 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- KLWUCTHALZWWTD-MOPGFXCFSA-N CC(C)(C)OC(N(CC[C@H]1F)C[C@@H]1NC1=NC(Cl)=NC2=C1C(C1CC1)=CN2COCC[Si](C)(C)C)=O Chemical compound CC(C)(C)OC(N(CC[C@H]1F)C[C@@H]1NC1=NC(Cl)=NC2=C1C(C1CC1)=CN2COCC[Si](C)(C)C)=O KLWUCTHALZWWTD-MOPGFXCFSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- MUXVXITYXXTDPO-OAQYLSRUSA-N CCN1N=CC(NC2=NC(N(COCC[Si](C)(C)C)C=C3C4CC4)=C3C(N[C@H](CCC3)CN3C(C=C)=O)=N2)=C1 Chemical compound CCN1N=CC(NC2=NC(N(COCC[Si](C)(C)C)C=C3C4CC4)=C3C(N[C@H](CCC3)CN3C(C=C)=O)=N2)=C1 MUXVXITYXXTDPO-OAQYLSRUSA-N 0.000 description 1
- DUPPWBWUUCMTFA-LJQANCHMSA-N CCN1N=CC(NC2=NC(N(COCC[Si](C)(C)C)C=C3C4CC4)=C3C(N[C@H]3CNCCC3)=N2)=C1 Chemical compound CCN1N=CC(NC2=NC(N(COCC[Si](C)(C)C)C=C3C4CC4)=C3C(N[C@H]3CNCCC3)=N2)=C1 DUPPWBWUUCMTFA-LJQANCHMSA-N 0.000 description 1
- WAKCOYYVHIONJR-UXHICEINSA-N CN(CC1)CCC1N1N=CC(NC2=NC(N(CO)C=C3C4CC4)=C3C(N[C@@H](CNCC3)[C@@H]3F)=N2)=C1 Chemical compound CN(CC1)CCC1N1N=CC(NC2=NC(N(CO)C=C3C4CC4)=C3C(N[C@@H](CNCC3)[C@@H]3F)=N2)=C1 WAKCOYYVHIONJR-UXHICEINSA-N 0.000 description 1
- NQAZRNADHPRNBW-UHFFFAOYSA-N CN1N=CC(NC2=NC(OC(CCC3)CCN3C(C=C)=O)=C(C(Cl)=CN3)C3=N2)=C1 Chemical compound CN1N=CC(NC2=NC(OC(CCC3)CCN3C(C=C)=O)=C(C(Cl)=CN3)C3=N2)=C1 NQAZRNADHPRNBW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 101000974353 Mus musculus Nuclear receptor coactivator 5 Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 102000000395 SH3 domains Human genes 0.000 description 1
- 108050008861 SH3 domains Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102000042834 TEC family Human genes 0.000 description 1
- 108091082333 TEC family Proteins 0.000 description 1
- 101710112793 Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 101710112791 Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101710112792 Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001334 alicyclic compounds Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- MWKAMUJIXBCKIH-WCQYABFASA-N benzyl (2s,5r)-5-amino-2-methylpiperidine-1-carboxylate Chemical compound C[C@H]1CC[C@@H](N)CN1C(=O)OCC1=CC=CC=C1 MWKAMUJIXBCKIH-WCQYABFASA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 108010021848 cyclosomatostatin Proteins 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- CMIBWIAICVBURI-SSDOTTSWSA-N tert-butyl (3r)-3-aminopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](N)C1 CMIBWIAICVBURI-SSDOTTSWSA-N 0.000 description 1
- FZAKOAFETOZBLC-SFYZADRCSA-N tert-butyl (3s,4r)-4-fluoro-3-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](F)[C@@H](O)C1 FZAKOAFETOZBLC-SFYZADRCSA-N 0.000 description 1
- CRFSWDBNKHNGGA-UHFFFAOYSA-N tert-butyl 4-hydroxyazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(O)CC1 CRFSWDBNKHNGGA-UHFFFAOYSA-N 0.000 description 1
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- OUMPIAFCFSHTFO-UHFFFAOYSA-N trimethyl-[2-[(2,4,5-trichloropyrrolo[2,3-d]pyrimidin-7-yl)methoxy]ethyl]silane Chemical compound N1=C(Cl)N=C2N(COCC[Si](C)(C)C)C=C(Cl)C2=C1Cl OUMPIAFCFSHTFO-UHFFFAOYSA-N 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 238000005533 tritiation Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010071941 | 2020-01-21 | ||
| CN202010071941X | 2020-01-21 | ||
| CN202011003941 | 2020-09-22 | ||
| CN2020110039412 | 2020-09-22 | ||
| PCT/CN2021/073081 WO2021147952A1 (fr) | 2020-01-21 | 2021-01-21 | Composé pyrimidopyrrole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115023428A true CN115023428A (zh) | 2022-09-06 |
Family
ID=76993282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180010090.0A Pending CN115023428A (zh) | 2020-01-21 | 2021-01-21 | 嘧啶并吡咯类化合物 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115023428A (fr) |
| WO (1) | WO2021147952A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114315838A (zh) * | 2020-09-30 | 2022-04-12 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202214643A (zh) * | 2020-09-22 | 2022-04-16 | 大陸商江蘇先聲藥業有限公司 | 嘧啶并吡咯類化合物 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102482277A (zh) * | 2009-05-05 | 2012-05-30 | 达纳-法伯癌症研究所有限公司 | 表皮生长因子受体抑制剂及治疗障碍的方法 |
| CN103748096A (zh) * | 2012-08-06 | 2014-04-23 | 美国艾森生物科学公司 | 作为蛋白激酶抑制剂的新型吡咯并嘧啶化合物 |
| CN103814030A (zh) * | 2011-09-22 | 2014-05-21 | 辉瑞大药厂 | 吡咯并嘧啶及嘌呤衍生物 |
| WO2018184206A1 (fr) * | 2017-04-07 | 2018-10-11 | ACEA Therapeutics, Inc. | Sels pharmaceutiques, formes physiques, compositions d'inhibiteurs kinases de pyrrolopyrimidine, et leurs procédés de préparation |
| CN109311896A (zh) * | 2016-06-30 | 2019-02-05 | 株式会社大熊制药 | 吡唑并嘧啶衍生物作为激酶抑制剂 |
| WO2019132561A1 (fr) * | 2017-12-28 | 2019-07-04 | 주식회사 대웅제약 | Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase |
| WO2019132562A1 (fr) * | 2017-12-28 | 2019-07-04 | 주식회사 대웅제약 | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase |
| WO2019132560A1 (fr) * | 2017-12-28 | 2019-07-04 | 주식회사 대웅제약 | Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase |
-
2021
- 2021-01-21 WO PCT/CN2021/073081 patent/WO2021147952A1/fr active Application Filing
- 2021-01-21 CN CN202180010090.0A patent/CN115023428A/zh active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102482277A (zh) * | 2009-05-05 | 2012-05-30 | 达纳-法伯癌症研究所有限公司 | 表皮生长因子受体抑制剂及治疗障碍的方法 |
| CN103814030A (zh) * | 2011-09-22 | 2014-05-21 | 辉瑞大药厂 | 吡咯并嘧啶及嘌呤衍生物 |
| CN103748096A (zh) * | 2012-08-06 | 2014-04-23 | 美国艾森生物科学公司 | 作为蛋白激酶抑制剂的新型吡咯并嘧啶化合物 |
| CN109311896A (zh) * | 2016-06-30 | 2019-02-05 | 株式会社大熊制药 | 吡唑并嘧啶衍生物作为激酶抑制剂 |
| WO2018184206A1 (fr) * | 2017-04-07 | 2018-10-11 | ACEA Therapeutics, Inc. | Sels pharmaceutiques, formes physiques, compositions d'inhibiteurs kinases de pyrrolopyrimidine, et leurs procédés de préparation |
| WO2019132561A1 (fr) * | 2017-12-28 | 2019-07-04 | 주식회사 대웅제약 | Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase |
| WO2019132562A1 (fr) * | 2017-12-28 | 2019-07-04 | 주식회사 대웅제약 | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase |
| WO2019132560A1 (fr) * | 2017-12-28 | 2019-07-04 | 주식회사 대웅제약 | Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114315838A (zh) * | 2020-09-30 | 2022-04-12 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021147952A1 (fr) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105732636B (zh) | 杂芳化合物及其在药物中的应用 | |
| CN104125959B (zh) | 作为btk活性的抑制剂的杂芳基吡啶酮和氮杂‑吡啶酮化合物 | |
| CN105732637B (zh) | 杂芳化合物及其在药物中的应用 | |
| WO2021088945A1 (fr) | Composé utilisé comme inhibiteur de shp2 et son utilisation | |
| AU2014356069A1 (en) | Novel amino pyrimidine derivatives | |
| TWI672304B (zh) | 作爲酪胺酸激酶抑制劑之經取代的乙炔基雜雙環化合物 | |
| CN107344940B (zh) | Btk抑制剂及其用途 | |
| CN104418860A (zh) | 嘧啶并杂环类化合物及其药用组合物和应用 | |
| JP2016528298A (ja) | Ｐｉｍキナーゼ阻害剤として有用なフロピリジン及びチエノピリジンカルボキシアミド化合物 | |
| WO2021139775A1 (fr) | Composé de pyridone et son application | |
| CN110950876B (zh) | 一类呋喃并内酰胺类化合物、制备方法和用途 | |
| EP3858833A1 (fr) | Dérivé d'aminonordécane, son procédé de préparation et son utilisation | |
| CN117062818A (zh) | 新型sos1抑制剂及其制备方法和应用 | |
| TW202116753A (zh) | 以噌啉作為hpk1的抑制劑 | |
| CN111560012A (zh) | 一种作为irak抑制剂的化合物 | |
| CN115023428A (zh) | 嘧啶并吡咯类化合物 | |
| JP2022540353A (ja) | チロシンキナーゼ２活性を仲介する複素環式化合物 | |
| TW202110848A (zh) | 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用 | |
| WO2018097234A1 (fr) | Nouveau dérivé d'oxoisoquinoline | |
| TW202241904A (zh) | 三環類化合物及其用途 | |
| CN112739420A (zh) | 苯氧基-吡啶基-嘧啶化合物及使用方法 | |
| KR20230142504A (ko) | Cdk 억제제 | |
| CN113735836A (zh) | 哒嗪类化合物及其应用 | |
| CN112654605B (zh) | 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途 | |
| WO2021147953A1 (fr) | Dérivé cyclique pyrimidino à cinq chaînons et application correspondante |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |